ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2019
APOL1 Genetic Testing in Living Kidney Transplant Donors.
Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Genetic kidney diseases: Decoding molecular taxonomies to drive precision nephrology and therapeutic innovation.Genes & diseases · 2027Review
- Advances in HLA and Non-HLA Immune Profiling: Integrating Next-Generation Sequencing and Artificial Intelligence in Transplantation.Annals of laboratory medicine · 2026Review
- Insights From Black Living Kidney Donors: An Interview Study on APOL1 Genetic Testing Experiences.Clinical transplantation · 2026Observational
- Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk.BMC nephrology · 2025Article
- Forging a path toward kidney transplant equity through multilevel interventions.Current opinion in organ transplantation · 2025Review
- Advancing Genetic Risk Assessment in Living Kidney Donation: A Comprehensive Approach to Patient Education and Counseling.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Attitudes Toward Use of an APOL1 Genetic Testing Chatbot in Living Kidney Donor Evaluation: A Focus Group Study.Clinical transplantation · 2024Article
- Nephrologists' Views on a Workflow for Returning Genetic Results to Research Participants.Kidney international reports · 2024Article
- Racial Equity in Living Donor Kidney Transplant Centers, 2008-2018.JAMA network open · 2023Article
- Genetic Counseling in Kidney Disease: A Perspective.Kidney medicine · 2023Article
- Implementation of a culturally competentBMJ open · 2023Article
- Impact of education on APOL1 testing attitudes among prospective living kidney donors.Clinical transplantation · 2022Article
- Practice Patterns in the Acceptance of Medically Complex Living Kidney Donors with Obesity, Hypertension, Family History of Kidney Disease, or Donor-Recipient Age Discrepancy.Avicenna journal of medicine · 2021Article
- APOL1 genotyping in kidney transplantation: to do or not to do, that is the question? (pro).Kidney international · 2021Article
- Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry.Transplantation direct · 2021Article
- Association Between Donor-Recipient Biological Relationship and Allograft Outcomes After Living Donor Kidney Transplant.JAMA network open · 2021Article
- Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Apolipoprotein L1: role in the evaluation of kidney transplant donors.Current opinion in nephrology and hypertension · 2020Article
- Article
- Using race in the estimation of glomerular filtration rates: time for a reversal?Current opinion in nephrology and hypertension · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The presence of 2 apolipoprotein L1 gene (APOL1) risk variants is associated with increased risk for chronic kidney disease and end-stage kidney disease. Inferior allograft outcomes following transplantation with kidneys from donors with 2 risk variants have also been reported. These data, coupled with anecdotal case reports and a recent cohort study of living donors, raise important questions about the potential increased kidney disease risk for living donors with APOL1 risk variants and the need for testing as part of the standard living donor evaluation process. We identify a series of questions that are central to the development of clinical policy regarding APOL1 testing of potential living kidney donors given the current uncertainty over the clinical implications of having 2 risk variants. We explore the ethical challenges that arise when determining when and to whom APOL1 testing should be offered, what potential donors should be told about APOL1 testing, how test results should be used to determine suitability for donation, if and when recipients should have access to results, and how clinical policy regarding APOL1 testing should be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.